NCT04476446View on ClinicalTrials.gov

An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

June 16, 2023

Study Completion Date

June 16, 2023

Conditions
Depression
Interventions
DRUG

Esketamine

Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.

Trial Locations (8)

4100

Ketamine Mexico S. de RL. de C.V., Mexico City

11000

Avalon Vinculación Médica En Salud Mental, Mexico City

Especialidades en Neuropsiquiatría de México S.C., México

11520

Hospital Espanol, Mexico City

11950

Clínica de Interdisciplinas Congnitivo Conductuales, México

44520

Clínica de Ansiedad, Depresión y Estrés CADE, S. de R.L. de C.V., Guadalajara

07000

Gabipros SC., Mexico City

01000

Ángel Alberto Ruiz Chow, México

All Listed Sponsors
lead

Janssen-Cilag, S.A.

INDUSTRY

NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives | Biotech Hunter | Biotech Hunter